The Joint European Congress on Head and Neck Oncology (ECHNO) and the International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO)

www.echno-ichno2021.org

Wednesday June 30 - Saturday July 3, 2021
Dear Friends of the EHNS,

Welcome to the online ECHNO/ICHNO 2021.

For the first time in our history, the Presidents of the three societies: EHNS, ESTRO and ESMO decided to join forces to organize two major scientific events together. The ECHNO/ICHNO 2021 online and ICHNO/ECHNO 2022 in traditional form in Brussels.

I would like to thank our ESMO and ESTRO partners, as well as our Colleagues from the Belgian Head and Neck Societies, for outstanding cooperation and preparation of a very compelling scientific programme. I am certain that all of the hard work of everyone involved in the organization of ECHNO/ICHNO 2021 will bear fruit in the form of a fantastic congress which you are all attending.

Wojciech Golusiński
European Head and Neck Society President

Committees

ORGANIZING COMMITTEE ECHNO
Prof. W. Golusiński EHNS President
Guy Andry Co-Chairman
Frederic Duprez Co-Chairman
Prof. Solange Peters ESMO President
Prof. Ben Slotman ESTRO President
Joke De Ceulaer
Paul Clement
Jean-François Daisne
Marc Hamoir
Olivier Lenssen
Jean-Pascal Machiels

SCIENTIFIC COMMITTEE – ICNHO
Pierre Blanchard FR Representing ESTRO
C. René Leemans NL Representing EHNS
JP Machiels BE Representing ESMO
Mererid Evans UK Chair of the Advisory Committee for Radiation Oncology
Sjoukje Oosting NL Chair of the Advisory Committee for Medical Oncology
Wojciech Golusiński Chair of the Advisory Committee for Surgery
Ruud Brakenhoff NL Chair of the Advisory Committee for Head and Neck Cancer Related Sciences

ADVISORY COMMITTEE FOR RADIATION ONCOLOGY
Mererid Evans UK Chair
Vincent Gregoire FR
Teresa Guerrero-Urbano UK
Florence Huguet FR
Hans Langendijk NL
Esat Mahmut Ozsahin CH
Claire Paterson UK
Silke Tribius DE
WEDNESDAY 30 JUNE 2021

14:40  Introduction to ECHNO-ICHNO 2021
Frédéric Duprez, Belgium and Guy Andry, Belgium

ASHNO - EHNS Session: head and neck oncology practice: any difference between Europe and Asia?

Chairs: EUR: Jesper Eriksen, Denmark & ASIA: Mohd Razif Mohamad Yunus, Malaysia

14:45  Introduction by chair/moderator
EUR: Jesper Eriksen, Denmark & ASIA: Mohd Razif Mohamad Yunus, Malaysia

15:00  Changing paradigms in head and neck surgery in Asia
Sheng-Po Hao, Taiwan

15:15  Update on nasopharyngeal cancer in Asia
Marlinda Adham, Indonesia

15:30  Epidemiology in head and neck cancer in Europe vs. Asia
Sefik Hosal, Turkey

15:45  Make sense campaign in Europe
Ana Ferreira Castr, Portugal

16:00  Concluding remarks
Jean Bourhis, Switzerland

Young Scientist’s Forum - Poster discussion from young scientists
Chairs: Pawel Golusinski, Poland & Amanda Psyrri, Greece & Piotr H. Skarzynski, Poland

16:30  Introduction
Wojciech Golusinski, Poland

16:35  0.1 Association of anemia and hematological inflammatory biomarkers with response to concurrent chemoradiotherapy on patients with squamous cell carcinoma of the head and neck
Joana Correia Magalhães, Portugal

16:45  0.2 Prospective validation of an institutional treatment strategy for T1N0M0 glottic carcinoma
Simon Beyaert, Belgium

16:55  0.3 Complications in transoral laser microsurgery for carcinoma of the larynx
Laura Ruiz Sevilla, Spain

Committees

ADVISORY COMMITTEE FOR MEDICAL ONCOLOGY
Sjoukje Oosting  NL  Chair
Paolo Bossi  IT
Irene Brana  ES
Ana Castro  PT
Robert Haddad  US
Ulrich Keilholz  DE
Christophe Le Tourneau  FR
Amanda Psyrri  GR
Anna Spreafico  CA

ADVISORY COMMITTEE FOR SURGERY
Wojchiech Golusiński  PL  Chair
Andreas Dietz  DE
Sefik Hosal  TR
Antti Mäkitie  FI
Haitham Mirghani  FR
Miguel Quer  ES
Gregorio Sanchez Aniceto  ES
Christian Simon  CH
Giovanni Succo  IT

ADVISORY COMMITTEE FOR HEAD AND NECK CANCER RELATED SCIENCES
Ruud Brakenhoff  NL  Chair
Robert Ferris  US
Jochen Hess  DE
Keith Hunter  UK
Claus Andrup Kristensen  DK
Max Robinson  UK
Susanne Singer  DE
Ingeborg Tinhofer-Keilholz  DE
Rieneke van de Ven  NL
THURSDAY 1 JULY 2021

08:30 Opening - by Presidents of EHNS, ESMO and ESTRO
Wojciech Golusinński, EHNS & Solange Peters, ESMO & Ben Slotman, ESTRO

08:40 Presidential Lecture
Chair: Wojciech Golusinński
Surgical Innovation: Essential for Optimal Multidisciplinary Care of Oropharyngeal Cancer
Chris Holsinger, USA

09:00 Best Presentation from Young Scientist’s Forum
Chairs: Pawel Golusinski & Amanda Psyrri

SESSION 1: FUTURE OF SURGICAL TREATMENTS.
Chair: Jan Klozar, Czech Republic & Moderator: René Leemans, The Netherlands

09:15 Is there a role of TORS in management of p16+ unknown primary cancer of the H&N?
Vinidh Paleri, United Kingdom

09:35 3D robotic like surgery
Giovanni Succo, Italy

09:55 Novel techniques for endoscopic skull base surgery
Antoine Moya-Plana, France

10:15 Image guided surgery
Max Witjes, The Netherlands

10:35 Coffee Break
SESSION 3: RECURRENT HEAD AND NECK CANCER—Salvage treatments in recurrent head and neck cancer

Chair: Vinita Paleri, United Kingdom & Moderator: Jean-François Daisne, Belgium

14:00 Salvage surgery for locally recurrent head and neck cancer
Miguel Quer, Spain

14:20 Locoregional reirradiation for recurrent head and neck cancer in the IMRT and SBRT era
Vincent Gregoire, France

14:40 Systemic therapy as monotherapy and in combination in head and neck cancer
Jan Vermorken, Belgium

PANEL: Salvage treatments in recurrent head and neck cancer: interactive case discussions

Moderators: Valentino Valentini, Italy & Antoine Digonnet, Belgium & Giovanni Succo, Italy

15:00 Panelists:
Radiotherapy: Kenneth Jensen, Denmark & Oncology: Sjoukje Oosting, The Netherlands & Oncology: Amanda Psyrri, Greece, Surgery: Gilles Dolivet, France; Surgery: Gregorio Sanchez Aniceto, Spain

15:40 Coffee Break

Preferred papers session 3

Chair: Antti Mäkitie, Finland & Moderator: Ben-Zion Joshua, Israel

16:15 3.1 A circulating biomarker for the early detection of recurrent oral cancer:
Cathie Garnis, Canada

16:25 3.2 Salvage Treatment in Isolated Regional Recurrent Head and Neck Squamous Cell Carcinoma
Roland Giger, Switzerland
FRIDAY 2 JULY 2021

SESSION 5: HOW TO COMBINE IMMUNOTHERAPY WITH STANDARD OF CARE

Chair: Andreas Dietz, Germany & Moderator: Ana Ferreira Castro, Portugal

08:30  Keynote lecture: Checkpoint inhibition in the radical setting for H&N SCC
Lisa Licitra, Italy

09:00  Neo-adjuvant immunotherapy in HNSCC
Charlotte Zuur, The Netherlands

09:15  Radiation with immunotherapy
Kevin Harrington, United Kingdom

09:30  Therapeutic vaccines in HPV+ disease
Christophe Le Tourneau, France

Proferred papers related to session 5

Chair: Drago Prgomet, Croatia & Moderator: Vincent Grégoire, France

09:45  5.1 Evaluation of pembrolizumab monotherapy in patients with salivary gland carcinoma in the phase 2 KEYNOTE-158 study
Caroline Evans, UK

09:55  5.2 Immune Tumor Microenvironment and Response to Chemotherapy in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas
Luis Juesas Iglesias, Spain

10:05  5.3 NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in patients with advanced cancers: phase I trial
Colette Shen, USA

10:15  Coffee Break

SESSION 4: SALIVARY GLAND TUMORS

Chair: Marc Hamoir, Belgium & Moderator: Gerhard Hüber, Switzerland

17:50  Keynote lecture: Histology-driven surgery in parotid carcinoma: fact or fiction?
Vincent Vanderpoorten, Belgium

18:10  Panelists:
Surgery: Sefik Hosal, Turkey & Radiotherapy: Jean Bourhis, Switzerland & Oncology: Laura Locati, Italy & Pathology: Andrzej Marszałek, Poland

18:50  End of congress day
SESSION 6: HOW WILL WE TREAT OUR PATIENTS NON-SURGICALLY IN 2030?

Chair: Jesper Grau-Eriksen, Denmark & Jean-Pascal Machiels, Belgium

10:45  Adaptive radiotherapy for dummies
       Edmond Sterpin, Belgium

11:05  Treatment adaptation for HPV positive disease.
       Pernille Lassen, Denmark

11:25  Systemic therapy: immune checkpoint inhibitors, still cisplatin, ...
       Sylvie Rottey, Belgium

Proferred papers related to session 6

Chair: Igor Reshetov, Russia & Moderator: Paul Clement, Belgium

11:45  6.1 Radiation enhancing hafnium oxide nanoparticles (NBTXR3) for the treatment of locally advanced HNSCC in elderly patients: a phase I/II study
       Christophe Le Tourneau, France

11:55  6.2 Validation of USPIO-enhanced MRI for detection of lymph node metastases in head and neck carcinoma: a pilot study
       Daphne Driessen, The Netherlands

12:05  6.3 Can imaging alone replace panendoscopy as a ‘gold standard’ investigation for patients with low risk features for oropharyngeal cancer?
       Carolina Watters, United Kingdom

12:15  6.4 The virtual MDT - the future or a fad?
       Hussein Mohamedbhai, UK

12:25  Concluding remarks

12:30  Lunch / virtual booth visit

12:45  Satellite Symposium Merck
       Visit page 18

SESSION 7: QUALITY OF CARE IN TREATMENT OF HEAD AND NECK CANCER AND SURVIVORSHIP

Chair: Andreas Dietz, Germany & Moderator: Giovanni Succo, Italy

14:00  How to improve Quality of Care in Surgical Oncology.
       René Leemans, The Netherlands

14:20  What really matters is the radiation oncologist behind the machine
       Vincent Grégoire, France

14:40  Optimizing the prescription doses and tolerability of systemic therapy
       Thorsten Fureder, Austria

15:00  Health related quality of life from diagnosis up to 2 years after treatment: evidence from NET-QUBIC
       Irma Verdonck-de Leeuw, The Netherlands

15:20  Value based health care.
       Yolande Lievens, Belgium

Proferred papers related to session 7

Chair: Fréderic Duprez, Belgium & Moderator: Susanne Singer, Germany

15:40  7.1 The positive yield of multidisciplinary team decisions in a high volume head and neck center after those made in its preferred partner: An example of enhanced quality of care
       J.J. Hendrickx, The Netherlands

15:50  7.2 Do head and neck cancer patients in randomized trials represent the population in daily practice?
       Johannes Kaanders, The Netherlands

16:00  Coffee Break
### SESSION 8: THYROID CANCER

**Chair:** Dimitrios Moraitis, Greece & **Moderator:** Guy Andry, Belgium

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>Surveillance vs. treatment of papillary thyroid cancer</td>
<td>Iain Nixon, United Kingdom</td>
</tr>
<tr>
<td>16:50</td>
<td>New treatment options in iodine-refractory thyroid cancer</td>
<td>Laura Locati, Italy</td>
</tr>
</tbody>
</table>

**Proferred papers related to session 8**

**Chair:** Ricard Simo, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:10</td>
<td><strong>8.1 Further progress in the detection of thyroid carcinoma: the microRNAs supplant the gene mutations in fine-needle aspiration biopsies.</strong></td>
<td>Marie Quiriny, France</td>
</tr>
<tr>
<td>17:20</td>
<td><strong>8.2 A Comparison of Differentiated Thyroid Cancer Presenting in the UK Versus Internationally</strong></td>
<td>Rupali Sawant, UK</td>
</tr>
<tr>
<td>17:30</td>
<td><strong>8.3 Ultrasound Scan Pre-Operative Localization of Recurrent Thyroid Cancer – Technique and Early Outcomes</strong></td>
<td>Chrysostomos Tornari, United Kingdom</td>
</tr>
<tr>
<td>17:40</td>
<td><strong>8.4 Correlation between thyroid fine needle aspiration cytology and post-operative histology: A 10-year single-centre experience</strong></td>
<td>Ahmad Abou-Foul, UK</td>
</tr>
<tr>
<td>17:50</td>
<td><strong>Concluding remarks</strong></td>
<td>Ricard Simo, United Kingdom</td>
</tr>
</tbody>
</table>

### SATURDAY 3 JULY 2021

**INVITED LECTURE**

**Chair:** Evaldas Padervinskis, Greece & **Moderator:** José Luis Cebrián Carretero, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Recommendations for treatment of head &amp; neck cancer in 2021 - EHNS, ESTRO and ESMO viewpoints</td>
<td>Amanda Psyrri, Greece</td>
</tr>
</tbody>
</table>

**Debate: this house believes that transoral surgery is the standard of care in early stage HPV+ oropharyngeal cancer**

**Chair:** Béatrix Barry, France & **Moderator:** Zhanna Kaliadzich, Belarus

<table>
<thead>
<tr>
<th>Time</th>
<th>For the motion</th>
<th>Against the motion</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Chris Holsinger, USA</td>
<td>Sandra Nuyts, Belgium</td>
</tr>
<tr>
<td>09:15</td>
<td>For the motion rebuttal</td>
<td>Christian Simon, Switzerland</td>
</tr>
<tr>
<td>09:30</td>
<td>Sandra Nuyts, Belgium</td>
<td>Against the motion rebuttal</td>
</tr>
<tr>
<td>09:45</td>
<td>Christian Simon, Switzerland</td>
<td>Jean Bourhis, Switzerland</td>
</tr>
</tbody>
</table>

**High level proferred papers/clinical trials with results**

**Chair:** Patrick Sheahan, Ireland & **Moderator:** Pierre Blanchard, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td><strong>9.1 Robotic lateral oropharyngectomy following diagnostic tonsillectomy is oncologically safe in patients with human papillomavirus related squamous cell cancer</strong></td>
<td>Samiah Siddiq, UK</td>
</tr>
<tr>
<td>10:10</td>
<td><strong>9.2 Transoral Laser Microsurgery for Oropharyngeal Squamous Cell Carcinoma: Results in Equitable Survival and Enhanced Function Compared with Contemporary Standards of Care</strong></td>
<td>C. Lucy Dalton, UK</td>
</tr>
</tbody>
</table>
Thursday 1 July - 12:45 - 14:00 hrs. Satellite symposium MDS

**Evolving Treatment Algorithms for 1L R/M HNSCC**

**Faculty**

- **Tanguy Seiwert**, Johns Hopkins University Medical Center, Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, USA
- **Jean-Pascal Machiels**, Saint-Luc University Clinics, Department of Internal Medicine, Medical Oncology Service, Brussels, Belgium
- **Denis Soulières**, University of Montreal Health, Centre (CHUM) Integrated Cancer Center (CICC), Montreal, Quebec, Canada

**Chair**: Jean-Pascal Machiels (Belgium)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>12:50</td>
<td>Advances in treatment of 1L R/M HNSCC</td>
</tr>
<tr>
<td>13:10</td>
<td>1L R/M HNSCC case studies with treatment algorithm discussions</td>
</tr>
<tr>
<td>13:25</td>
<td>Future/ongoing development in HNSCC</td>
</tr>
<tr>
<td>13:45</td>
<td>Q&amp;A and closing remarks</td>
</tr>
</tbody>
</table>

**EHNS, ESMO and ESTRO: future events, other important messages from the societies**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td><strong>EHNS</strong></td>
</tr>
<tr>
<td>10:40</td>
<td>Wojciech Golusinski, Poland</td>
</tr>
<tr>
<td>10:50</td>
<td><strong>ESMO</strong></td>
</tr>
<tr>
<td>11:00</td>
<td>Solange Peters, Switzerland</td>
</tr>
<tr>
<td>11:05</td>
<td><strong>ESTRO</strong></td>
</tr>
<tr>
<td>11:10</td>
<td>Pierre Blanchard, France</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>ICHNO-ECHNO 2022 Brussels announcement</strong></td>
</tr>
<tr>
<td>11:05</td>
<td>Pierre Blanchard, France</td>
</tr>
<tr>
<td>11:10</td>
<td><strong>ECHNO Lisbon Portugal 2023 announcement</strong></td>
</tr>
<tr>
<td>11:10</td>
<td>Ana Castro, Portugal</td>
</tr>
<tr>
<td>11:10</td>
<td><strong>Concluding remarks of the congress</strong></td>
</tr>
<tr>
<td>11:10</td>
<td>Frederic Duprez, Belgium &amp; Guy Andry, Belgium</td>
</tr>
</tbody>
</table>

**9.3 Treatment outcomes and survival following definitive (chemo) radiotherapy in HPV+ oropharynx cancer: Large scale comparison of two population-based cohorts**

*Pernille Lassen, Denmark*
DOES ONE SIZE FIT ALL? – PERSONALIZING TREATMENT IN R/M SCCHN

Faculty
Prof. Paolo Bossi (Italy), PD Philipp Ivanyi (Chairperson, Germany), and Prof. Joël Guigay (France)

12:45 – 12:47 Introductory remarks
Philipp Ivanyi

12:47 – 12:59 Key factors in treatment decisions: The importance of patient needs
Paolo Bossi

12:59 – 13:11 The evolving treatment landscape: Matching treatments to patients
Philipp Ivanyi

13:11 – 13:23 Treatment sequencing in R/M SCCHN: 1L and beyond
Joël Guigay

13:23 – 13:43 Putting the data into practice
All speakers

13:43 – 13:45 Closing remarks
Philipp Ivanyi

13:45 – 14:00 Live discussion
All speakers
Does one size fit all?
Personalizing treatment for R/M SCCHN

Join to hear expert insights at the ECHNO-ICHNO Virtual Congress 2021

Date: Friday 2nd July 2021
Time: 12:45–14:00 CEST

Philipp Ivanyi, Paolo Bossi, Joël Guigay

Introductory remarks
Philipp Ivanyi, Germany

Key factors in treatment decisions:
The importance of patient needs
Paolo Bossi, Italy

The evolving treatment landscape:
Matching treatments to patients
Philipp Ivanyi, Germany

Treatment sequencing in R/M SCCHN:
1L and beyond
Joël Guigay, France

Putting the data into practice
All

Closing remarks
Philipp Ivanyi, Germany

Live discussion
All

GL-ERBSCCHN-00166 | Date of preparation: June 2021
ECHNO-ICHNO2021 Congress Secretariat

Congress Care
P.O. Box 440
5201 AK 's-Hertogenbosch
The Netherlands
Tel: +31-73-690 1415
E: info@congresscare.com
www.congresscare.com